FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026 LIFESTYLE PROGRAM IMPROVES BRAIN HEALTH AMONG OLDER ADULTS AT RISK FOR DEMENTIA ACROSS LATIN AMERICA
- LatAm-FINGERS Study Findings Confirm and Expand U.S. POINTER Trial Results - - Show Structured Dementia Risk Reduction Strategies Adaptable Across Cultures - Key Takeaways The LatAm-FINGERS study shows lifestyle interventions adapted across Latin...
NYSE Content Update: Versigent To Ring Opening Bell As its Shares Debut for Trade
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 1, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market...
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD VIS-101 demonstrated...
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
HONG KONG, June 16, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the...